Inclusion Criteria:

- All patients undergoing planned allogeneic transplant (both malignant and
non-malignant diagnoses)

- Patients with an oncology diagnosis that are on a chemotherapy regimen that will last
for an additional >= 3 months; patients with an oncology diagnosis that will be on a
chemotherapy regimen for >= 3 months

- Patients must have, or be scheduled to have, an external tunneled central venous
catheter (CVC) (Broviacs, Hickmans, tunneled percutaneously inserted central catheter
(PICCs), etc.) that is expected to remain in place for an additional >= 3 months

Exclusion Criteria:

- Patients with a previous or current line infection are ineligible until 14 days after
the completion of antibiotics

- Subjects who would enroll in the Oncology Patient stratum who are planned to start
conditioning for HCT within 3 months of enrollment are ineligible

- Patients with only non-tunneled CVCs (non-tunneled peripherally inserted central
catheters [PICCs], temporary CVCs, midline catheters, etc) are ineligible

- Patients with only totally implanted CVCs or ports are ineligible

- Patients with a known allergy or hypersensitivity to CHG are ineligible

- Patients with chronic, severe, generalized skin breakdown (such as generalized
blistering, burns, severe graft versus host disease [GVHD] with open sores, etc.) are
ineligible

- Patients enrolled on ACCL0934 are ineligible

- Patients scheduled to receive broad-spectrum prophylactic antibacterial therapy are
ineligible

- Patients receiving sorafenib at the time of enrollment or as part of a treatment plan
scheduled to receive sorafenib are ineligible

- Patients using prophylactic antimicrobial locks in the CVC at the time of enrollment
or as part of a treatment plan scheduled to receive prophylactic antimicrobial locks
in the CVC are ineligible

- Patients previously enrolled on this trial are ineligible